Labopharm completes joint venture with Gruppo Angelini

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has completed the previously announced transaction to establish a joint venture with Gruppo Angelini. The joint venture, Angelini Labopharm, will launch OLEPTRO(TM), Labopharm's novel once-daily formulation of trazodone indicated for the treatment of major depressive disorder in adults, in the U.S. in the third quarter of this year.

Terms of the joint venture agreement will be available in Labopharm's related regulatory filings with SEDAR and EDGAR.


Labopharm Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.